2016 Review: Refocus, Reduce, Reform The Watchwords In Japan
While reimbursement pricing issues and policies dominated the Japanese pharma market in 2016, there was also notable commercial activity during the year, although this was more about refocusing and reducing rather than major mergers and acquisitions.
You may also be interested in...
Join Scrip and the Pink Sheet’s Asia content team for a wide-ranging look at the ongoing multiple impacts of the pandemic on the pharma industry.
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.